NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia Therapeutics (NTLA) shares fell 22.9% following an update from its Phase III MAGNITUDE study of nexiguran ziclumeran (nex-z) for ATTR amyloidosis with cardiomyopathy (ATTR-CM), after a patient experienced grade 4 liver transaminase elevations; while the event resolved without intervention, investors appear concerned about the long-term safety of the gene therapy candidate. The MAGNITUDE study is ongoing with enrollment expected to complete by 2027, while a separate Phase III study for ATTR amyloidosis with polyneuropathy (ATTRv-PN) is also underway, with potential BLA submission planned for 2028.

Analysis

Intellia Therapeutics (NTLA) experienced a significant 22.9% decline in its share price following the disclosure of a grade 4 liver transaminase elevation in a patient participating in the Phase III MAGNITUDE study for its in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), intended for ATTR amyloidosis with cardiomyopathy. Although the patient was asymptomatic and the adverse event reportedly resolved without medical intervention, this development has evidently stoked investor concerns regarding the long-term safety profile of nex-z, contributing to NTLA's year-to-date share plunge of 36.1%, markedly underperforming the industry's 5.4% decline. The MAGNITUDE study's enrollment is projected to complete by 2027, while a parallel Phase III study (MAGNITUDE 2) for nex-z in ATTR amyloidosis with polyneuropathy aims for enrollment completion in 2026 and a potential Biologics License Application by 2028. Regeneron Pharmaceuticals (REGN), which has a co-development and co-promotion agreement for nex-z, shares 25% of its development costs and commercial profits, thus also bearing exposure to these trial developments. While Intellia also progresses another pipeline candidate, NTLA-2002 for hereditary angioedema, with a Phase III HAELO study expecting enrollment completion in Q3 2025, the recent adverse event with nex-z underscores the inherent complexities and high-stakes nature of developing CRISPR-based therapies.

Key Decisions for Investors

• Investors should exercise heightened caution with Intellia Therapeutics, closely monitoring forthcoming data from the nex-z Phase III studies for further safety signals and efficacy results, given the severe market reaction to this single adverse event.
• The protracted development timelines for nex-z, with enrollment completion for the ATTR-CM study not expected until 2027 and a potential BLA submission for ATTRv-PN by 2028, necessitate a long-term investment horizon and careful evaluation of Intellia's risk-reward profile.
• Shareholders in Regeneron Pharmaceuticals should consider the potential impact of nex-z's clinical progress and safety profile on REGN, due to its 25% co-development and co-promotion stake in the candidate.